Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on Invested CapitalReturn on SalesTimes Interest Earned

Ascendis Pharma A (ASND) EBITDA Margin (2016 - 2025)

Historic EBITDA Margin for Ascendis Pharma A (ASND) over the last 12 years, with Q4 2025 value amounting to 13.76%.

  • Ascendis Pharma A's EBITDA Margin rose 78800.0% to 13.76% in Q4 2025 from the same period last year, while for Dec 2025 it was 31.35%, marking a year-over-year increase of 729200.0%. This contributed to the annual value of 32.16% for FY2025, which is 715200.0% up from last year.
  • Latest data reveals that Ascendis Pharma A reported EBITDA Margin of 13.76% as of Q4 2025, which was up 78800.0% from 29.29% recorded in Q3 2025.
  • Over the past 5 years, Ascendis Pharma A's EBITDA Margin peaked at 13.76% during Q4 2025, and registered a low of 13140.61% during Q2 2021.
  • For the 5-year period, Ascendis Pharma A's EBITDA Margin averaged around 1762.45%, with its median value being 281.09% (2023).
  • Its EBITDA Margin has fluctuated over the past 5 years, first plummeted by -65195100bps in 2021, then surged by 118082000bps in 2022.
  • Quarter analysis of 5 years shows Ascendis Pharma A's EBITDA Margin stood at 130.71% in 2021, then plummeted by -393bps to 643.75% in 2022, then soared by 95bps to 29.2% in 2023, then rose by 26bps to 21.64% in 2024, then soared by 36bps to 13.76% in 2025.
  • Its EBITDA Margin stands at 13.76% for Q4 2025, versus 29.29% for Q3 2025 and 25.47% for Q2 2025.